We found that MEF2C and FLT3 were both expressed at higher levels in ETP-ALL than in typical T-ALL patients (MEF2C: p = 0.039, FLT3: p = 0.014) (Table 1, Fig 1). This evidence concerns the gene MEF2C and acute lymphoblastic leukemia.